Long-Term Efficacy And Safety Of Two Posterior Chamber Phakic Intraocular Lenses For Myopia Correction: A Four-Year Contralateral Eye Study

To compare the long-term efficacy and safety of the phakic refractive intraocular lens (PR), a new posterior chamber phakic intraocular lens (PIOL), with the Implantable Collamer Lens (ICL) for myopia correction.

Aier Eye Hospital, Guangzhou, Affiliated to Jinan University

This retrospective study included 10 patients (20 eyes) who underwent implantation of the PR and ICL in the contralateral eye serving as the control, with a follow-up period of 4 years. Two PIOLs were compared for their efficacy, safety, vault stability, visual symptoms, and patient satisfaction at 4 years postoperatively.

At 4 years postoperatively, no significant differences were observed between the PR and ICL groups for UDVA and CDVA, uncorrected and distance-corrected near visual acuity, refractive outcomes, anterior segmental parameters, IOP, ECD and higher-order aberrations (P > .05). Both groups achieved 20/20 or better UDVA in 100.0% of eyes. The mean efficacy index and safety index were 1.19 ± 0.14 and 1.43 ± 0.34 in the PR group, while 1.23 ± 0.24 and 1.37 ± 0.35 in the ICL group, respectively. Central and peripheral vaults showed no significant reduction in the PR group (P > .05), whereas both vaults were significantly reduced in the ICL group (P < .05). Peripheral vault in the PR group was significantly wider than that in the ICL group (P < .05).

At 4 years postoperatively, the phakic refractive intraocular lens were effective and safe in myopia correction, with clinical outcomes comparable to those of the ICL, while offering the additional advantages of more stable vaults and a wider peripheral vault.